Sold as Intron A. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Interferon Alfa-2b (sold as Intron A), first approved Jun 4, 1986, with 7 new uses approved and 0 published complete response letters.
| Interferon-α Maintenance in Favorable-Risk AMLAML (Acute Myeloid Leukemia) · Peking University People's Hospital | Phase 2 | Recruiting | Nov 9, 2026 |
| Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCHBV-HCC, Unresectable Advanced HBV-related Liver Cancer · Jinling Hospital, China | Not applicable | Recruiting | Aug 18, 2026 |
| Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic SinusitisChronic Rhinosinusitis Without Polyps · The First Affiliated Hospital of Xinxiang Medical College | Early phase 1 | Not yet recruiting | Jun 9, 2026 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaEssential Thrombocythemia · Incyte Corporation | Phase 3 | Recruiting | Jun 3, 2026 |
| Risk Factors for Tooth Eruption DiseasesTooth Eruption Disorder · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Not yet recruiting | May 14, 2026 |
| Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionHepatocellular Carcinoma, HEPATITIS B CHRONIC · Ningbo No.2 Hospital | Early phase 1 | Not yet recruiting | Apr 28, 2026 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaAtypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia · Jonsson Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Mar 13, 2026 |
| A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PVPolycythemia Vera (PV) · Duan Minghui | Not applicable | Recruiting | Mar 3, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Schering